Bayer’s cancer treatment Stivarga has been granted priority review status by the FDA for use as a second line treatment of unresectable hepatocellular carcinoma (uHCC). Already approved for use ...
Four new drugs are expected to be launched in China in this period: Amgen/Takeda's Vectibix, Bayer's Stivarga, Sanofi's Zaltrap, and Taiho Pharmaceutical's Lonsurf, with Bayer's drug expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback